150 related articles for article (PubMed ID: 37954918)
1. Feasibility of home dose optimization of apomorphine sublingual film in Parkinson's disease patients with OFF episodes: results from the dose-optimization phase of an open-label, randomized crossover study.
Kassubek J; Stocchi F; Martinez EB; Pahwa R; Ondo W; Zhang Y; Bowling A; Pappert E; Isaacson S; Wu S;
Ther Adv Neurol Disord; 2023; 16():17562864231209240. PubMed ID: 37954918
[TBL] [Abstract][Full Text] [Related]
2. Apomorphine Sublingual Film Compared with Subcutaneous Apomorphine for OFF Episodes in Parkinson's Disease: An Open-Label, Randomized, Crossover Study.
Stocchi F; Rascol O; Poewe W; Chaudhuri KR; Kassubek J; Lopez Manzanares L; Zhang Y; Bowling A; Pappert E; Wu S;
J Parkinsons Dis; 2023; 13(8):1329-1342. PubMed ID: 37980683
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson's disease complicated by OFF episodes: a phase 3, open-label study.
Kassubek J; Factor SA; Balaguer E; Schwarz J; Chaudhuri KR; Isaacson SH; Wu S; Denecke Muhr C; Kulisevsky J
J Neurol; 2024 Jun; 271(6):3554-3570. PubMed ID: 38546829
[TBL] [Abstract][Full Text] [Related]
4. Dose Optimization of Apomorphine Sublingual Film for OFF Episodes in Parkinson's Disease: Is the Prophylactic Use of an Antiemetic Necessary?
Hauser RA; Ondo WG; Zhang Y; Bowling A; Navia B; Pappert E; Isaacson SH;
J Parkinsons Dis; 2023; 13(3):403-414. PubMed ID: 36970914
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson's Disease and "OFF" Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study.
Agbo F; Isaacson SH; Gil R; Chiu YY; Brantley SJ; Bhargava P; Navia B
Neurol Ther; 2021 Dec; 10(2):693-709. PubMed ID: 33991326
[TBL] [Abstract][Full Text] [Related]
6. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
Olanow CW; Factor SA; Espay AJ; Hauser RA; Shill HA; Isaacson S; Pahwa R; Leinonen M; Bhargava P; Sciarappa K; Navia B; Blum D;
Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699
[TBL] [Abstract][Full Text] [Related]
7. Open-label titration of apomorphine sublingual film in patients with Parkinson's disease and "OFF" episodes.
Hui JS; Fox SH; Neeson W; Bhargava P; Pappert E; Blum D; Navia B;
Parkinsonism Relat Disord; 2020 Oct; 79():110-116. PubMed ID: 32927285
[TBL] [Abstract][Full Text] [Related]
8. A Randomized Thorough QT Study of Apomorphine Sublingual Film in Patients With Parkinson's Disease.
Stocchi F; Peckham EL; De Pandis MF; Sciarappa K; Kleiman R; Agbo F; Olanow CW; Blum D; Navia B
Clin Pharmacol Drug Dev; 2022 Sep; 11(9):1068-1077. PubMed ID: 35899977
[TBL] [Abstract][Full Text] [Related]
9. An open-label, uncontrolled dose-optimization study of sublingual apomorphine in erectile dysfunction.
Mulhall JP; Bukofzer S; Edmonds AL; George M;
Clin Ther; 2001 Aug; 23(8):1260-71. PubMed ID: 11558862
[TBL] [Abstract][Full Text] [Related]
10. Motor response with apomorphine sublingual film and levodopa in patients with OFF episodes.
Isaacson SH; Bowling A; Zhang I; Pappert E; Stocchi F;
Neurodegener Dis Manag; 2023 Apr; 13(2):75-84. PubMed ID: 36562349
[No Abstract] [Full Text] [Related]
11. Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study.
Katzenschlager R; Poewe W; Rascol O; Trenkwalder C; Deuschl G; Chaudhuri KR; Henriksen T; van Laar T; Lockhart D; Staines H; Lees A
Parkinsonism Relat Disord; 2021 Feb; 83():79-85. PubMed ID: 33486139
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Apomorphine Sublingual Film as an "On-Demand" Treatment for "OFF" Episodes in Patients with Parkinson's Disease.
Thach A; Kirson N; Zichlin ML; Dieye I; Pappert E; Williams GR
J Health Econ Outcomes Res; 2021; 8(2):82-92. PubMed ID: 35178465
[No Abstract] [Full Text] [Related]
13. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease.
Hauser RA; Olanow CW; Dzyngel B; Bilbault T; Shill H; Isaacson S; Dubow J; Agro A
Mov Disord; 2016 Sep; 31(9):1366-72. PubMed ID: 27430123
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose.
Pahwa R; Koller WC; Trosch RM; Sherry JH;
J Neurol Sci; 2007 Jul; 258(1-2):137-43. PubMed ID: 17466338
[TBL] [Abstract][Full Text] [Related]
15. Dose optimization of apomorphine sublingual film for treating "OFF" episodes in Parkinson's disease.
Olanow CW; Stocchi F; Peckham EL; De Pandis MF; Sciarappa K; Navia B
Parkinsonism Relat Disord; 2021 Dec; 93():27-30. PubMed ID: 34763305
[TBL] [Abstract][Full Text] [Related]
16. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
17. A European multicentre study to evaluate the tolerability of apomorphine sublingual administered in a forced dose-escalation regimen in patients with erectile dysfunction.
Von Keitz AT; Ströberg P; Bukofzer S; Mallard N; Hibberd M
BJU Int; 2002 Mar; 89(4):409-15. PubMed ID: 11872034
[TBL] [Abstract][Full Text] [Related]
18. Intermittent subcutaneous apomorphine therapy for 'off' episodes in Parkinson's disease: a 6-month open-label study.
Trosch RM; Silver D; Bottini PB
CNS Drugs; 2008; 22(6):519-27. PubMed ID: 18484793
[TBL] [Abstract][Full Text] [Related]
19. ND0701, A Novel Formulation of Apomorphine for Subcutaneous Infusion, in Comparison to a Commercial Apomorphine Formulation: 28-Day Pharmacokinetic Study in Minipigs and a Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Relative Bioavailability.
Ramot Y; Nyska A; Adar L; Durlach C; Fishelovitch D; Sacco G; Manno RA; Oren S; Perlstein I; Yacobi-Zeevi O
CNS Drugs; 2018 May; 32(5):443-454. PubMed ID: 29637529
[TBL] [Abstract][Full Text] [Related]
20. A critical review of apomorphine hydrochloride sublingual film for the treatment of Parkinson's disease 'OFF' episodes.
Caughman CY; Factor S
Expert Rev Neurother; 2021 Feb; 21(2):169-177. PubMed ID: 33227223
[No Abstract] [Full Text] [Related]
[Next] [New Search]
